EICHORPublic-registry site landscape for NCT03078322, “AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression”, a Major Depressive Disorder study sponsored by VistaGen Therapeutics, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT03078322 (registry record) |
| Study title | AV-101 as Adjunct Antidepressant Therapy in Patients With Major Depression |
| Official title | Double-Blind, Placebo-Controlled, Phase 2 Trial to Test Efficacy and Safety of AV-101 (L-4-chlorokynurenine) as Adjunct to Current Antidepressant Therapy in Patients With Major Depressive Disorder (the ELEVATE Study) |
| Sponsor | VistaGen Therapeutics, Inc. |
| Condition(s) | Major Depressive Disorder |
| Phase | PHASE2 |
| Listed sites | 22 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT03078322.
Eichor generates a preliminary site-risk snapshot for NCT03078322 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Major Depressive Disorder trials
← Eichor home · All tracked trials · Major Depressive Disorder studies · Weekly briefs
